OnCo
technologiesTechnologyStandard of care

Liver transplantation for cancer (Milan criteria and beyond)

Replacing the whole diseased liver cures both the cancer and the cirrhosis underneath it, for patients whose tumours are small enough.

Mazzaferro's Milan criteria (1996: one tumour ≤5 cm or up to three ≤3 cm, no vascular invasion) yield ~70% five-year survival. Expanded criteria (UCSF, up-to-seven, AFP-adjusted) and downstaging with TACE/TARE widen eligibility; living-donor transplantation (Asan Medical Center performs the world's highest volume) relieves organ shortage. Transplantation for unresectable colorectal liver metastases (TRANSMET, 2024) and perihilar cholangiocarcinoma (Mayo protocol) is expanding.

Generic schematic · not to scale · placeholder for the surgery front
Patient-side cart · Wristed instrument arms · Target through 8 mm ports

How it works

Total hepatectomy and grafting removes the tumour and the pre-malignant cirrhotic field; immunosuppression is balanced against recurrence risk.

Strengths
  • Only therapy that treats cancer and cirrhosis together
  • Best long-term survival for early HCC
Limitations
  • Organ shortage and waiting-list dropout
  • Lifelong immunosuppression; checkpoint inhibitors before transplant risk rejection
Since
1996

Latest papers

top
Literature trend1 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Liver transplantation for cancer" OR ABSTRACT:"Liver transplantation for cancer" OR TITLE:"Milan criteria and beyond" OR ABSTRACT:"Milan criteria and beyond") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Liver transplantation for cancer (Milan criteria and beyond), not a curated reading list.

Connected

13top